|
MRSN | Mersana Therapeutics, Inc. |
|
|
MRSN | Mersana Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -0.13 |
| Leverage | 106.57% |
| Market Cap | $ 70.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -68.9m |
| Margin | -154.14% |
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of Antibody Drug Conjugates (ADCs) for cancer patients with unmet needs. The company is headquartered in Cambridge, Massachusetts.